Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business Wire • Friday
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a BetZacks Investment Research • 09/13/24
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical ExecutionBusiness Wire • 09/12/24
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain StockZacks Investment Research • 09/11/24
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare ConferenceBusiness Wire • 09/04/24
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel DealBusiness Wire • 09/03/24
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to TradeZacks Investment Research • 08/28/24
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple SclerosisBusiness Wire • 08/09/24
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/01/24
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 08/01/24
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside SummitBusiness Wire • 07/08/24
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025Business Wire • 06/27/24
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.Business Wire • 06/20/24
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver CongressBusiness Wire • 06/05/24
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?Zacks Investment Research • 05/29/24
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 05/13/24
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private PlacementBusiness Wire • 05/08/24
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire • 05/07/24
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire • 05/07/24